Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories. It also provides Cochlear true wireless devices comprising mini microphones, phone clips, and TV streamers; and Cochlear Vistafix bone-anchored facial prosthetic solutions to enhance the attachment and cosmetic outcome of facial prostheses. The company has strategic collaborations with Sensorion and GN Hearing A/S to focus on improving hearing outcomes in patients with cochlear implants. Cochlear Limited was incorporated in 1983 and is headquartered in Sydney, Australia.
Industry, Sector and Symbol
Stock Exchange ASX
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolASX:COH
Previous Symbol
CUSIPN/A
Phone+61-2-94286555
Debt
Debt-to-Equity Ratio24.18
Current Ratio2.03
Quick Ratio1.35
Price-To-Earnings
Trailing P/E Ratio39.96
Forward P/E Ratio34.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.36 billion
Price / SalesN/A
Cash FlowA$1.06 per share
Price / Cash Flow160.80
Book ValueA$10.61 per share
Price / Book16.07
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees3,500
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable
Cochlear (ASX:COH) Frequently Asked Questions
What is Cochlear's stock symbol?
Cochlear trades on the ASX under the ticker symbol "COH."
Has Cochlear been receiving favorable news coverage?
Press coverage about COH stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cochlear earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Cochlear's key competitors?
Some companies that are related to Cochlear include Activecare (ACAR), Advanced Oncotherapy (AVO), Airware Labs (AIRW), Anteo Diagnostics (ADO), Aurora Spine (ASG), Avacta Group (AVCT), Azure Healthcare (AZV), Biosig Technologies (BSGM), Cannabix Technologies (BLOZF), ConvaTec Group (CTEC), Creo Medical Group (CREO), Draegerwerk AG & Co KGaA (DRW3), Electromed (ELMD), Ellex Medical Lasers (ELXMF) and Fisher & Paykel Healthcare (FPH).
Who are Cochlear's key executives?
Cochlear's management team includes the folowing people:
- Mr. Diggory William Howitt, CEO, MD, Pres & Exec. Director (Age 51)
- Mr. Brent Andrew Cubis, Chief Financial Officer
- Mr. Jan Janssen, Chief Technology Officer
- Mr. Richard Brook, Pres of EMEA & Latin American Region
- Mr. Anthony Manna, Pres of Americas Region
What is Cochlear's stock price today?
One share of COH stock can currently be purchased for approximately A$170.53.
What is Cochlear's official website?
How can I contact Cochlear?
Cochlear's mailing address is 1 University Avenue Macquarie University, SYDNEY, NSW 2109, Australia. The company can be reached via phone at +61-2-94286555.
MarketBeat Community Rating for Cochlear (ASX COH)
MarketBeat's community ratings are surveys of what our community members think about Cochlear and other stocks. Vote "Outperform" if you believe COH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COH will underperform the S&P 500 over the long term. You may vote once every thirty days.
